Free NCI-MATCH keeps enrolling—Targeted mutations are proving to be less common than estimated July 07, 2017Vol.43 No.27By Paul Goldberg
Conversation with The Cancer LetterFree Keith Flaherty: We will certainly stop if we enroll all subprotocols July 07, 2017Vol.43 No.27By Paul Goldberg
Conversation with The Cancer LetterFree Barbara Conley: Learning from first broad foray into precision medicine July 07, 2017Vol.43 No.27By Paul Goldberg
Free James Doroshow: NCI-MATCH tests ability to integrate next generation sequencing July 07, 2017Vol.43 No.27
Drugs & Targets FDA approves Vectibix for use in wild-type ras metastatic colorectal cancer July 06, 2017Vol.40 No.06
